Cancer Clinical Trials: Proactive Strategies (Record no. 249312)

MARC details
000 -LEADER
fixed length control field 04813nam a22004695i 4500
001 - CONTROL NUMBER
control field 978-0-387-33225-3
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20160614135649.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 100301s2007 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9780387332253
-- 978-0-387-33225-3
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-0-387-33225-3
Source of number or code doi
049 ## - LOCAL HOLDINGS (OCLC)
Holding library Alfaisal Main Library
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC254-282
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED062000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 616.994
Edition number 23
245 10 - TITLE STATEMENT
Title Cancer Clinical Trials: Proactive Strategies
Medium [electronic resource] /
Statement of responsibility, etc edited by Stanley P. L. Leong.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE STATEMENTS
Place of production, publication, distribution, manufacture Boston, MA :
Name of producer, publisher, distributor, manufacturer Springer US,
Date of production, publication, distribution, manufacture 2007.
300 ## - PHYSICAL DESCRIPTION
Extent XX, 320 p.
Other physical details online resource.
336 ## - CONTENT TYPE
Content Type Term text
Content Type Code txt
Source rdacontent
337 ## - MEDIA TYPE
Media Type Term computer
Media Type Code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier Type Term online resource
Carrier Type Code cr
Source rdacarrier
347 ## -
-- text file
-- PDF
-- rda
490 1# - SERIES STATEMENT
Series statement Cancer Treatment and Research,
International Standard Serial Number 0927-3042 ;
Volume number/sequential designation 132
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Historical Perspective and Evolving Concerns for Human Research -- Cancer Trials and the Institutional Review Board (IRB) -- NCI’s Cancer Therapy Evaluation Program: A Commitment to Treatment Trials -- The Role of the FDA in Cancer Clinical Trials -- The Role of Cooperative Groups in Cancer Clinical Trials -- The Advocate Role in Clinical Study Development and Partnering with Patient Advocates in Your Local Institution -- The National Breast Cancer Coalition: Setting the Standard for Advocate Collaboration in Clinical Trials -- The Role of the Principal Investigator in Cancer Clinical Trials -- The Audit Process and How to Ensure a Successful Audit -- The Privacy Rule (HIPAA) as it Relates to Clinical Research -- The Commission on Cancer, American College of Surgeons’ Response to HIPAA -- Ethical and Legal Issues in the Conduct of Cancer Clinical Trials -- The Role of the Office of Research Integrity in Cancer Clinical Trials -- Strategies for the Administration of a Clinical Trials Infrastructure: Lessons from a Comprehensive Cancer Center -- The Clinical Research Process: Building a System in Harmony with its Users -- Cancer Research and Clinical Trial in Action: An Important Exercise Before You Embark on Your Study.
520 ## - SUMMARY, ETC.
Summary, etc Foreword written by Samuel A. Wells, Jr., MD Professor of Surgery Duke University Medical Center, Durham, NC According to the American Cancer Society, about 1 million persons in the United States will be diagnosed with solid cancer every year. About 50% of them will be potentially cured by surgery. The other half of the population may develop metastatic cancer. To date, there is no systemic treatment available to cure metastatic cancer. Therefore, cancer clinical trials are critical to evaluate reliable treatment modalities against metastatic cancer. Likewise, adjuvant trials are needed to prevent high risk patients from developing recurrence following definitive surgical resection of their cancer. Only about 3-5% of the adult cancer patients are enrolled in clinical trials. When the pediatric cancer clinical trial groups were able to accrue over 40 percent of eligible patients to their clinical trials, significant impact was made on the survival of these pediatric cancer patients. However, multiple barriers exist to block adult cancer patients from entering into clinical protocols. The ever-changing regulations for clinical trials and the ethical dilemma of treating cancer patients as subjects have made it ever so difficult for the principal investigators to conduct clinical research, especially when they are often ill-informed of the complex nature of the regulations and over-worked. Therefore, cancer clinical trials are at a critical junction. The objective of this book is to bring the issues of cancer clinical trials into focus so that proactive strategies may be developed to make such trials more user-friendly. Ultimately, the cancer patients will be benefited. "Clinical trials remain the most important vehicle for improving the care of cancer patients. This text presents the fundamental components and challenges involving clinical investigations. Leading experts discuss the critical issues covering the spectrum of important topics from planning to application." Steven T. Rosen, M.D. Series Editor.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Oncology.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine & Public Health.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Oncology.
655 #7 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Electronic books.
Source of term local
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Leong, Stanley P. L.
Relator term editor.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9780387332246
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title Cancer Treatment and Research,
-- 0927-3042 ;
Volume number/sequential designation 132
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://ezproxy.alfaisal.edu/login?url=http://dx.doi.org/10.1007/978-0-387-33225-3">http://ezproxy.alfaisal.edu/login?url=http://dx.doi.org/10.1007/978-0-387-33225-3</a>
912 ## -
-- ZDB-2-SME
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Library of Congress Classification
Koha item type eBooks

No items available.

Copyright © 2020 Alfaisal University Library. All Rights Reserved.
Tel: +966 11 2158948 Fax: +966 11 2157910 Email:
librarian@alfaisal.edu